“`html
A New Jersey federal judge ruled on Monday that several patents concerning Teva-brand asthma inhalers were “improperly listed in the Orange Book,” a decision that U.S. Federal Trade Commission (FTC) Chair Lina Khan quickly acknowledged.
This ruling has significant implications for Teva Pharmaceuticals and the broader pharmaceutical industry, as the Orange Book listing can affect market exclusivity and competitive dynamics in the drug marketplace. Chair Khan’s acknowledgement suggests that the FTC may play a more active role in scrutinizing pharmaceutical patent listings and practices.
Further details about the ruling and its potential impact can be found in the original report by Law360 here.
“`